2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
https://t.co/0POS80XBM2
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney- Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease
https://t.co/qYy5qTptsL
#Perspective: CAC scanning remains the preferred imaging tool for cardiovascular risk stratification in most asymptomatic patients. CCTA should be reserved for select high-risk populations. https://t.co/DjPf3fr0d6
In this sham-controlled trial of 60 patients with symptomatic atrial fibrillation, pulsed field ablation (PFA) was superior to sham in reducing arrhythmia recurrence & burden and improving QOL. https://t.co/iZqzeZILK7
Lifestyle intervention-induced visceral adipose tissue (VAT) loss may persist despite weight regain and confer lasting cardiometabolic benefits: VAT loss, not weight loss, may be the key target for durable cardiometabolic health. https://t.co/uHef45YF0d
Upregulated BACH1 is involved in pulmonary hypertension pathogenic mechanisms. BACH1 inhibition may be a novel therapeutic strategy for idiopathic PAH @eosto1@jiayi Lin https://t.co/dc5Ou5jyWB
NAP is a key circulating metabolite linking intestinal injury to cardiac toxicity and provides a potential biomarker for monitoring cardiovascular risk in microplastic exposed populations. https://t.co/YePUpEJJvJ
Co-published by @ACPinternists and @AHAScience#AHAJournals, @AnnalsofIMCC is a peer-reviewed, open access journal that publishes #casereports, case series, and image/video cases across the spectrum of medicine. Learn more and submit to AIMCC today at https://t.co/IzoNqdQ2Qo